It's been a wild week for the stock markets. The Dow plunged below 1,000 points for the second time ever on Thursday. We ask Chris Versace, Chief Investment Officer at Tematica Research, what's behind the big ups and downs. Versace is not concerned about the recent 10% drop but adds that everyone should be if the market drops another 10%. Still, he cautions young people who may be worried to stay in the market.
Amazon is taking on UPS and FedEx, announcing a new delivery service geared towards businesses. The service, called "Shipping with Amazon," will pick up packages from businesses and ship them to customers. Amazon will launch this service in Los Angeles in the coming weeks.
Congress agreed on a spending bill after a brief government shutdown overnight. The House voted around 5 AM eastern time on Friday morning, and then President Trump signed the bill hours later. The spending bill will add hundreds of billions of dollars to the federal deficit.
Snapchat is starting to show signs of recovery after a disappointing few quarters. Cheddar senior reporter Alex Heath sits down with Billy Gallagher, author of the new book "How to Turn Down a Billion Dollars: The Snapchat Story," to see what lies ahead for the company. Gallagher was in a fraternity with Snapchat co-founder and CEO Evan Spiegel.
The health and wellness industry is booming, expected to hit $14 trillion by 2032. Equinox teamed up with Function Health to revolutionize health optimization.
Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.
The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!
Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.
In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d